
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
666.87 (USD) • At close March 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Regeneron Pharmaceuticals, Inc. |
Symbool | REGN |
Munteenheid | USD |
Prijs | 666.87 |
Beurswaarde | 71,693,859,960 |
Dividendpercentage | 0% |
52-weken bereik | 642 - 1,211.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Leonard S. Schleifer M.D., Ph.D. |
Website | https://www.regeneron.com |
An error occurred while fetching data.
Over Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)
